|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu ZH, Lin C, Liu MM, Zhang J, Tao ZH and
Hu XC: Src inhibition can synergize with gemcitabine and reverse
resistance in triple negative breast cancer cells via the AKT/c-Jun
pathway. PLoS One. 11:e01692302016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen M, He M, Song Y, Chen L, Xiao P, Wan
X, Dai F and Shen P: The cytoprotective role of gemcitabine-induced
autophagy associated with apoptosis inhibition in triple-negative
MDA-MB-231 breast cancer cells. Int J Mol Med. 34:276–282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Sousa Cavalcante L and Monteiro G:
Gemcitabine: Metabolism and molecular mechanisms of action,
sensitivity and chemoresistance in pancreatic cancer. Eur J
Pharmacol. 741:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hesse M and Arenz C: MicroRNA maturation
and human disease. Methods Mol Biol. 1095:11–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gommans WM and Berezikov E: Controlling
miRNA regulation in disease. Methods Mol Biol. 822:1–18. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Selcuklu SD, Donoghue MT, Rehmet K, de
Souza Gomes M, Fort A, Kovvuru P, Muniyappa MK, Kerin MJ, Enright
AJ and Spillane C: MicroRNA-9 inhibition of cell proliferation and
identification of novel miR-9 targets by transcriptome profiling in
breast cancer cells. J Biol Chem. 287:29516–29528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu M, Xu Y, Ge M, Gui Z and Yan F:
Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell
proliferation and apoptosis. Cancer Sci. 106:833–839. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pouliot LM, Chen YC, Bai J, Guha R, Martin
SE, Gottesman MM and Hall MD: Cisplatin sensitivity mediated by
WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer
Res. 72:5945–5955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv J, Xia K, Xu P, Sun E, Ma J, Gao S,
Zhou Q, Zhang M, Wang F, Chen F, et al: miRNA expression patterns
in chemoresistant breast cancer tissues. Biomed Pharmacother.
68:935–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park EY, Chang E, Lee EJ, Lee HW, Kang HG,
Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, et al: Targeting of
miR34a-NOTCH1 axis reduced breast cancer stemness and
chemoresistance. Cancer Res. 74:7573–7582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen L and Bourguignon LY: Hyaluronan-CD44
interaction promotes c-Jun signaling and miRNA21 expression leading
to Bcl-2 expression and chemoresistance in breast cancer cells. Mol
Cancer. 13:522014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Wang YW, Xing AY, Xiang S, Shi DB,
Liu L, Li YX and Gao P: Suppression of SPIN1-mediated PI3K-Akt
pathway by miR-489 increases chemosensitivity in breast cancer. J
Pathol. 239:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dorman SN, Baranova K, Knoll JH, Urquhart
BL, Mariani G, Carcangiu ML and Rogan PK: Genomic signatures for
paclitaxel and gemcitabine resistance in breast cancer derived by
machine learning. Mol Oncol. 10:85–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eriksson S, Skog S, Tribukait B and
Jäderberg K: Deoxyribonucleoside triphosphate metabolism and the
mammalian cell cycle. Effects of thymidine on wild-type and dCMP
deaminase-deficient mouse S49 T-lymphoma cells. Exp Cell Res.
155:129–140. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu YZ and Plunkett W: Modulation of
deoxycytidylate deaminase in intact human leukemia cells. Action of
2′,2′-difluorodeoxycytidine. Biochem Pharmacol. 44:1819–1827. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsaur I, Makarević J, Juengel E, Gasser M,
Waaga-Gasser AM, Kurosch M, Reiter M, Wedel S, Bartsch G, Haferkamp
A, et al: Resistance to the mTOR-inhibitor RAD001 elevates integrin
α2- and β1-triggered motility, migration and invasion of prostate
cancer cells. Br J Cancer. 107:847–855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee SY, Im SA, Park YH, Woo SY, Kim S,
Choi MK, Chang W, Ahn JS and Im YH: Genetic polymorphisms of
SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with
metastatic breast cancer receiving gemcitabine plus paclitaxel
chemotherapy. Eur J Cancer. 50:698–705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O'Reilly EA, Gubbins L, Sharma S, Tully R,
Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell
M and McCann A: The fate of chemoresistance in triple negative
breast cancer (TNBC). BBA Clin. 3:257–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosell R, Cobo M, Isla D, Camps C and
Massuti B: Pharmacogenomics and gemcitabine. Ann Oncol. 17 (Suppl
5):v13–v16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rajabpour A, Afgar A, Mahmoodzadeh H,
Radfar JE, Rajaei F and Teimoori-Toolabi L: MiR-608 regulating the
expression of ribonucleotide reductase M1 and cytidine deaminase is
repressed through induced gemcitabine chemoresistance in pancreatic
cancer cells. Cancer Chemother Pharmacol. 80:765–775. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhuang J, Shen L, Yang L, Huang X, Lu Q,
Cui Y, Zheng X, Zhao X, Zhang D, Huang R, et al: TGFβ1 promotes
gemcitabine resistance through regulating the
LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer.
Theranostics. 7:3053–3067. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang X, Taeb S, Jahangiri S, Korpela E,
Cadonic I, Yu N, Krylov SN, Fokas E, Boutros PC and Liu SK: miR-620
promotes tumor radioresistance by targeting 15-hydroxyprostaglandin
dehydrogenase (HPGD). Oncotarget. 6:22439–22451. 2015.PubMed/NCBI
|
|
27
|
Ueno H, Kiyosawa K and Kaniwa N:
Pharmacogenomics of gemcitabine: Can genetic studies lead to
tailor-made therapy? Br J Cancer. 97:145–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu H, Wang Z, Li M, Zeng F, Wang K, Huang
R, Wang H, Yang F, Liang T, Huang H and Jiang T: Gene expression
and methylation analyses suggest DCTD as a prognostic factor in
malignant glioma. Sci Rep. 7:115682017. View Article : Google Scholar : PubMed/NCBI
|
